Letrozol Genthon (Letrozole)

Letrozole blocks the aromatase enzyme, which converts androgens into estrogens in peripheral tissues. Inhibiting this conversion reduces circulating estrogen, depriving estrogen‑sensitive cancer cells of a key growth signal and thereby limiting tumor progression.

The prescribed dose of letrozole is determined by the treating physician based on the patient’s clinical condition, renal and hepatic function, and other individual factors. Healthcare professionals follow established guidelines but should not rely on a fixed dosage without medical assessment.

Letrozole is classified as pregnancy category X, meaning it is contraindicated during pregnancy because it can cause fetal harm. It is also not recommended for breastfeeding mothers, as it may pass into breast milk and affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Letrozole and other third‑generation aromatase inhibitors such as anastrozole and exemestane share a similar mechanism of estrogen suppression. Letrozole is often chosen for its once‑daily dosing and potent aromatase inhibition, though individual response and tolerability may guide the selection of a specific agent.

Store Letrozol Genthon tablets at ambient temperature below 25 °C, in the original container, and protect them from moisture and direct sunlight. Keep out of reach of children and do not use if the packaging is damaged.

Letrozol Genthon is taken orally, usually with a glass of water. The tablet should be swallowed whole and not crushed or chewed. It can be taken with or without food, according to the prescriber’s instructions.

Serious adverse events include severe liver injury, osteoporotic fractures, deep‑vein thrombosis, pulmonary embolism, myocardial infarction, and rare severe skin reactions such as Stevens‑Johnson syndrome. Patients should report any signs of liver dysfunction, unusual bruising, chest pain, or severe skin rash promptly.

Letrozol Genthon is contraindicated in pregnant women, premenopausal women, and individuals with known hypersensitivity to letrozole or any excipients. Caution is also advised for patients with severe hepatic impairment, uncontrolled osteoporosis, or a history of thromboembolic events.